The FDA’s 1-2 week delay on the Ampligen decision has now stretched into nearly a month. While this kind of thing is hardly uncommon with the FDA, as time drags on with no announcement people are wondering if something more is going on. At least one Wall Street blogger thinks Ampligen’s manufacturer, Hemispherx Biopharma Inc., will withdraw its application rather than have it turned down. That would save the company some embarrassment and allow it to focus its energy on studies of Ampligen for swine flu (H1N1). Then again, this particular blogger has been hammered for spreading misinformation about both the drug and the company, so it’s hard to say whether his opinion carries any weight.